

# Marius M Hoeper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1957774/publications.pdf>

Version: 2024-02-01

225  
papers

34,160  
citations

10986  
71  
h-index

3650  
180  
g-index

229  
all docs

229  
docs citations

229  
times ranked

18560  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | The Value of C-Arm Computed Tomography in Addition to Conventional Digital Subtraction Angiography in the Diagnostic Work-up of Patients with Suspected Chronic Thromboembolic Pulmonary Hypertension: An Update of 300 Patients. <i>Academic Radiology</i> , 2022, 29, S1-S10. | 2.5 | 6         |
| 2  | Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.   | 6.7 | 57        |
| 3  | Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 411-420.  | 0.6 | 4         |
| 4  | COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.   | 6.7 | 124       |
| 5  | Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1583.   | 4.1 | 16        |
| 6  | Childhood Trauma in Patients With PAH—Prevalence, Impact on QoL, and Mental Health—A Preliminary Report. <i>Frontiers in Psychiatry</i> , 2022, 13, 812862.   | 2.6 | 0         |
| 7  | Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation. <i>European Respiratory Journal</i> , 2022, 60, 2103087.   | 6.7 | 7         |
| 8  | Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.  | 0.6 | 28        |
| 9  | Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?. <i>European Heart Journal</i> , 2022, 43, 3432-3434.   | 2.2 | 6         |
| 10 | Health Disparities and Differences in Health-Care-Utilization in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 813506.  | 2.6 | 3         |
| 11 | Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 821468.   | 2.6 | 1         |
| 12 | Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis. <i>Cells</i> , 2022, 11, 664.  | 4.1 | 12        |
| 13 | Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 821466.   | 2.6 | 7         |
| 14 | Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. <i>Respiratory Research</i> , 2022, 23, 74.  | 3.6 | 18        |
| 15 | Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 971-981.  | 0.6 | 9         |
| 16 | Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study. <i>Critical Care</i> , 2022, 26, 92.  | 5.8 | 8         |
| 17 | Metacognitive Short-Term Intervention in Patients With Mental Disorders Following Cardiovascular Events. <i>Frontiers in Psychiatry</i> , 2022, 13, 812807.   | 2.6 | 1         |
| 18 | Application of the REVEAL risk score calculator 2.0 in the CHEST study. <i>Respiratory Medicine</i> , 2022, 195, 106783.  | 2.9 | 1         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. <i>European Heart Journal</i> , 2022, 43, 3387-3398.   | 2.2  | 69        |
| 20 | Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 812812.   | 2.6  | 2         |
| 21 | Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?. <i>Genes</i> , 2022, 13, 759.  | 2.4  | 2         |
| 22 | Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. <i>Critical Care</i> , 2022, 26, 134.  | 5.8  | 21        |
| 23 | Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.  | 10.7 | 57        |
| 24 | Effect of Therapeutic Plasma Exchange on Immunoglobulin Deficiency in Early and Severe Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1491-1497.  | 2.8  | 8         |
| 25 | Current and future treatments of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2021, 178, 6-30.  | 5.4  | 104       |
| 26 | Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L590-L599.  | 2.9  | 17        |
| 27 | Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.   | 2.9  | 23        |
| 28 | Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <i>Cellular and Molecular Immunology</i> , 2021, 18, 936-944.  | 10.5 | 98        |
| 29 | Impact of unilateral diaphragm elevation on postoperative outcomes in bilateral lung transplantation – a retrospective single-center study. <i>Transplant International</i> , 2021, 34, 474-487.   | 1.6  | 8         |
| 30 | Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. <i>European Respiratory Journal</i> , 2021, 57, 2004455.  | 6.7  | 42        |
| 31 | COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.  | 14.3 | 177       |
| 32 | Motion Reduction for C-Arm Computed Tomography of the Pulmonary Arteries: Image Quality of a Motion Correction Algorithm in Patients with Chronic Thromboembolic Hypertension During Balloon Pulmonary Angioplasty. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 1074-1080. | 1.3  | 2         |
| 33 | Response to Badagliacca et al: Multi-dimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 167-168.   | 0.6  | 0         |
| 34 | Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.   | 2.9  | 13        |
| 35 | Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 229-233.   | 0.6  | 28        |
| 36 | Circulating cardiovascular microRNAs in critically ill COVID-19 patients. <i>European Journal of Heart Failure</i> , 2021, 23, 468-475.  | 7.1  | 107       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 531-549.  | 7.3  | 43        |
| 38 | High Incidence of Epileptiform Potentials During Continuous EEG Monitoring in Critically Ill COVID-19 Patients. Frontiers in Medicine, 2021, 8, 613951.  | 2.6  | 0         |
| 39 | Extracorporeal membrane oxygenation in non-intubated immunocompromised patients. Critical Care, 2021, 25, 164.   | 5.8  | 8         |
| 40 | Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.   | 27.0 | 224       |
| 41 | Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis, 2021, 52, 791-796.  | 2.1  | 6         |
| 42 | Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine, 2021, 34, 100822.  | 7.1  | 22        |
| 43 | Pregnancy in PAH: Reality is changing. Journal of Heart and Lung Transplantation, 2021, 40, 395-396.   | 0.6  | 2         |
| 44 | Liver-first strategy for a combined lung and liver transplant in patients with cystic fibrosis. European Journal of Cardio-thoracic Surgery, 2021, 60, 822-830.  | 1.4  | 2         |
| 45 | Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 667602.  | 2.6  | 30        |
| 46 | Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension. BMC Pulmonary Medicine, 2021, 21, 164.   | 2.0  | 2         |
| 47 | C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection, 2021, 49, 935-943.  | 4.7  | 76        |
| 48 | Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine, the, 2021, 9, 573-584.  | 10.7 | 85        |
| 49 | Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 668647.   | 2.6  | 9         |
| 50 | Application of the REVEAL risk score calculator 2.0 in the PATENT study. International Journal of Cardiology, 2021, 332, 189-192.  | 1.7  | 5         |
| 51 | Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. Journal of Heart and Lung Transplantation, 2021, 40, 494-503. | 0.6  | 20        |
| 52 | Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. Clinical Infectious Diseases, 2021, 73, 2000-2008.   | 5.8  | 30        |
| 53 | Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1256-1257.  | 4.5  | 9         |
| 54 | Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286.  | 0.8  | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2021, 58, 2101483. | 6.7 | 48        |
| 56 | Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.  | 0.8 | 55        |
| 57 | Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 872-881.                                       | 0.6 | 3         |
| 58 | Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1172-1180.   | 0.6 | 9         |
| 59 | ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.  | 6.7 | 287       |
| 60 | Depiction of mosaic perfusion in chronic thromboembolic pulmonary hypertension (CTEPH) on C-arm computed tomography compared to computed tomography pulmonary angiogram (CTPA). <i>Scientific Reports</i> , 2021, 11, 20042.    | 3.3 | 0         |
| 61 | Gas exchange: the neglected piece in the PAH puzzle. <i>European Respiratory Journal</i> , 2021, 58, 2101407.   | 6.7 | 0         |
| 62 | Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 57.  | 1.9 | 13        |
| 63 | Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 781532.                           | 2.6 | 5         |
| 64 | Extracorporeal Membrane Oxygenation for Severe ARDS Due to Immune Diffuse Alveolar Hemorrhage. <i>Chest</i> , 2020, 157, 744-747.   | 0.8 | 14        |
| 65 | Nonocclusive Mesenteric Ischemia and Interventional Local Vasodilatory Therapy: A Meta-Analysis and Systematic Review of the Literature. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 128-139.                         | 2.8 | 13        |
| 66 | Pulmonary Artery Denervation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 927-929.   | 2.8 | 3         |
| 67 | Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.   | 0.6 | 104       |
| 68 | Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.   | 6.1 | 109       |
| 69 | Extracorporeal portosystemic shunt in secondary Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2020, 73, 974-976.   | 3.7 | 1         |
| 70 | Enoximone in status asthmaticus. <i>ERJ Open Research</i> , 2020, 6, 00367-2019.  | 2.6 | 4         |
| 71 | Blood carbon dioxide tension and risk in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2020, 318, 131-137.  | 1.7 | 12        |
| 72 | Recurrent Life-threatening Pneumonitis in a 37-Year-Old Woman. <i>Chest</i> , 2020, 158, e127-e132.   | 0.8 | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Risk stratification in pulmonary arterial hypertension using Bayesian analysis. European Respiratory Journal, 2020, 56, 2000008.   | 6.7  | 38        |
| 74 | Mechanical circulatory support in refractory cardiogenic shock due to influenza virus-related myocarditis. European Respiratory Journal, 2020, 56, 2000925.  | 6.7  | 7         |
| 75 | Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology, 2020, 317, 188-192.                                  | 1.7  | 5         |
| 76 | Subtle signs “red flags. European Respiratory Journal, 2020, 55, 2000606.  | 6.7  | 1         |
| 77 | Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Critical Care, 2020, 24, 71.   | 5.8  | 36        |
| 78 | Therapeutic plasma exchange in acute on chronic liver failure. Journal of Clinical Apheresis, 2020, 35, 316-327.   | 1.3  | 10        |
| 79 | Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. Circulation, 2020, 141, 678-693.  | 1.6  | 139       |
| 80 | Chronic Thromboembolic Pulmonary Hypertension Perioperative Monitoring Using Phase-Resolved Functional Lung (PREFUL)-MRI. Journal of Magnetic Resonance Imaging, 2020, 52, 610-619.                    | 3.4  | 17        |
| 81 | Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. Journal of Critical Care, 2020, 57, 124-129.  | 2.2  | 25        |
| 82 | Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309.   | 0.6  | 39        |
| 83 | Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease. American Journal of Pathology, 2020, 190, 1382-1396.  | 3.8  | 9         |
| 84 | Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. Frontiers in Cardiovascular Medicine, 2020, 7, 51.                        | 2.4  | 16        |
| 85 | Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation. Journal of Heart and Lung Transplantation, 2020, 39, 915-925.                                 | 0.6  | 28        |
| 86 | Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. European Respiratory Journal, 2020, 56, 2000616.   | 6.7  | 22        |
| 87 | Therapeutic plasma exchange in acute liver failure. Journal of Clinical Apheresis, 2019, 34, 589-597.  | 1.3  | 42        |
| 88 | Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine, the, 2019, 7, 594-604. | 10.7 | 119       |
| 89 | Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. Lancet Respiratory Medicine, the, 2019, 7, 780-790.     | 10.7 | 139       |
| 90 | Maintenance Immunosuppression Is Associated With Better Outcome in the 2017/2018 Influenza Epidemic. Open Forum Infectious Diseases, 2019, 6, ofz381.  | 0.9  | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , 2019, 20, 208.                                    | 3.6 | 16        |
| 92  | Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1286-1295.             | 0.6 | 62        |
| 93  | Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801880.   | 6.7 | 9         |
| 94  | Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 748-756.  | 0.6 | 29        |
| 95  | Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to <i>Pneumocystis</i> pneumonia. <i>European Respiratory Journal</i> , 2019, 54, 1900410.                                       | 6.7 | 7         |
| 96  | The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. <i>European Respiratory Journal</i> , 2019, 53, 1900038.   | 6.7 | 44        |
| 97  | Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802004.   | 6.7 | 68        |
| 98  | Extracorporeal membrane oxygenation and surgical embolectomy for high-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2019, 53, 1801773.  | 6.7 | 21        |
| 99  | The revised definition of pulmonary hypertension: exploring the impact on patient management. <i>European Heart Journal Supplements</i> , 2019, 21, K4-K8.   | 0.1 | 55        |
| 100 | “Better be awake” a role for awake extracorporeal membrane oxygenation in acute respiratory distress syndrome due to <i>Pneumocystis</i> pneumonia. <i>Critical Care</i> , 2019, 23, 418.                        | 5.8 | 11        |
| 101 | C-Arm computed tomography (CACT)-guided balloon pulmonary angioplasty (BPA): Evaluation of patient safety and peri- and post-procedural complications. <i>European Radiology</i> , 2019, 29, 1276-1284.          | 4.5 | 22        |
| 102 | Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 194-202. | 0.6 | 19        |
| 103 | Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. <i>Arthritis and Rheumatology</i> , 2019, 71, 805-816.                               | 5.6 | 25        |
| 104 | Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients. <i>European Radiology</i> , 2019, 29, 1693-1702.  | 4.5 | 27        |
| 105 | Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801906.   | 6.7 | 144       |
| 106 | Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. <i>Clinical Research in Cardiology</i> , 2018, 107, 548-553.  | 3.3 | 77        |
| 107 | REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 836-843.                                      | 0.6 | 29        |
| 108 | Risk assessment in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1702606.   | 6.7 | 67        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.  | 2.8 | 82        |
| 110 | The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clinical Research in Cardiology, 2018, 107, 460-470.   | 3.3 | 29        |
| 111 | Quantitation of Perfused Lung Volume Using Hybrid SPECT/CT Allows Refining the Assessment of Lung Perfusion and Estimating Disease Extent in Chronic Thromboembolic Pulmonary Hypertension. Clinical Nuclear Medicine, 2018, 43, e170-e177.                                     | 1.3 | 24        |
| 112 | Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?. European Journal of Heart Failure, 2018, 20, 256-259.   | 7.1 | 3         |
| 113 | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI <sub>2</sub> ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408. | 0.6 | 15        |
| 114 | REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519.  | 0.6 | 29        |
| 115 | Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Critical Care, 2018, 22, 307.   | 5.8 | 81        |
| 116 | Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research, 2018, 19, 258.  | 3.6 | 39        |
| 117 | Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. European Respiratory Journal, 2018, 52, 1800248.   | 6.7 | 61        |
| 118 | Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Critical Care, 2018, 22, 285.  | 5.8 | 113       |
| 119 | Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. Journal of Heart and Lung Transplantation, 2018, 37, 1410-1417.   | 0.6 | 15        |
| 120 | Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 37-45.   | 1.7 | 56        |
| 121 | Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 69-78.   | 1.7 | 140       |
| 122 | Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 46-52.                              | 1.7 | 33        |
| 123 | MRI-derived Regional Biventricular Function in Patients with Chronic Thromboembolic Pulmonary Hypertension Before and After Pulmonary Endarterectomy. Academic Radiology, 2018, 25, 1540-1547.  | 2.5 | 15        |
| 124 | Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 1235-1244.   | 0.6 | 26        |
| 125 | Age, risk and outcomes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800629.  | 6.7 | 9         |
| 126 | Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients. Intensive Care Medicine, 2018, 44, 1483-1492.  | 8.2 | 46        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | Chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: to screen or not to screen?. European Respiratory Journal, 2018, 51, 1800440.   | 6.7  | 3         |
| 128 | Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. European Heart Journal, 2017, 38, ehw597.   | 2.2  | 83        |
| 129 | Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.   | 0.6  | 22        |
| 130 | Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2017, 49, 1602522.  | 6.7  | 32        |
| 131 | First identification of <i>SMAD4</i> mutation in heritable pulmonary arterial hypertension. Clinical Science, 2017, 131, 689-698.   | 4.3  | 38        |
| 132 | Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respiratory Medicine, 2017, 128, 50-56.   | 2.9  | 31        |
| 133 | Predicting recurrent pulmonary embolism and chronic thromboembolic pulmonary hypertension: one more way to skin the cat. European Respiratory Journal, 2017, 49, 1700413.   | 6.7  | 1         |
| 134 | Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. European Respiratory Journal, 2017, 49, 1602409.   | 6.7  | 178       |
| 135 | Chronic thromboembolic pulmonary hypertension: Evaluation of 2D-perfusion angiography in patients who undergo balloon pulmonary angioplasty. European Radiology, 2017, 27, 4264-4270.   | 4.5  | 24        |
| 136 | An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. European Respiratory Review, 2017, 26, 160121.   | 7.1  | 156       |
| 137 | Mid-term results of bilateral lung transplant with postoperatively extended intraoperative extracorporeal membrane oxygenation for severe pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2017, 52, 163-170.                                       | 1.4  | 48        |
| 138 | Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22. | 2.9  | 15        |
| 139 | RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.  | 6.7  | 113       |
| 140 | Is there a vanishing pulmonary capillary syndrome?. Lancet Respiratory Medicine, 2017, 5, 676-678.  | 10.7 | 22        |
| 141 | Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.   | 6.7  | 489       |
| 142 | More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. European Respiratory Journal, 2017, 50, 1700354.  | 6.7  | 25        |
| 143 | The answer is blowing in the wind: an uncommon cause for severe ARDS accompanied by circulatory insufficiency requiring extracorporeal membrane oxygenation. BMJ Case Reports, 2017, 2017, bcr2016218079.   | 0.5  | 2         |
| 144 | Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulmonary Medicine, 2017, 17, 216.  | 2.0  | 23        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 145 | Pulmonary Hypertension. Deutsches A&#x0308;rztblatt International, 2017, 114, 73-84.  | 0.9  | 87        |
| 146 | State of the Art: Bridging to lung transplantation using artificial organ support technologies. Journal of Heart and Lung Transplantation, 2016, 35, 1385-1398.   | 0.6  | 29        |
| 147 | Residual Pulmonary Hypertension After Pulmonary Endarterectomy. Circulation, 2016, 133, 1731-1733.  | 1.6  | 13        |
| 148 | Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 372-380.                | 10.7 | 130       |
| 149 | Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901. | 10.7 | 59        |
| 150 | Successful use of extracorporeal membrane oxygenation during induction chemotherapy in a patient with mediastinal tumor mass of a T lymphoblastic lymphoma. Annals of Hematology, 2016, 95, 1719-1721.  | 1.8  | 16        |
| 151 | Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 368-378.   | 2.8  | 244       |
| 152 | C-Arm Computed Tomography Adds Diagnostic Information in Patients with Chronic Thromboembolic Pulmonary Hypertension and a Positive V/Q SPECT. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2016, 189, 49-56.             | 1.3  | 6         |
| 153 | Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance. European Radiology, 2016, 26, 4064-4071.   | 4.5  | 36        |
| 154 | CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respiratory Research, 2016, 17, 21.   | 3.6  | 26        |
| 155 | Pulmonary Artery Imaging in Patients with Chronic Thromboembolic Pulmonary Hypertension: Comparison of Cone-Beam CT and 64-Row Multidetector CT. Journal of Vascular and Interventional Radiology, 2016, 27, 361-368.e2.  | 0.5  | 22        |
| 156 | MR Imagingâ€derived Regional Pulmonary Parenchymal Perfusion and Cardiac Function for Monitoring Patients with Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. Radiology, 2016, 279, 925-934.                            | 7.3  | 54        |
| 157 | Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. Clinical Research in Cardiology, 2016, 105, 283-296.   | 3.3  | 197       |
| 158 | Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. International Journal of Infectious Diseases, 2016, 42, 1-3.    | 3.3  | 11        |
| 159 | Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2016, 133, 859-871.  | 1.6  | 506       |
| 160 | A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.   | 10.7 | 523       |
| 161 | Diffusion Capacity and Mortality in PatientsâWith Pulmonary Hypertension Dueâto Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 441-449.  | 4.1  | 95        |
| 162 | Incidence and prevalence of pulmonary arterial hypertension in Germany. International Journal of Cardiology, 2016, 203, 612-613.  | 1.7  | 60        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 163 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.   | 2.2  | 5,074     |
| 164 | Comparison of C-arm Computed Tomography and Digital Subtraction Angiography in Patients with Chronic Thromboembolic Pulmonary Hypertension. CardioVascular and Interventional Radiology, 2016, 39, 53-63.  | 2.0  | 37        |
| 165 | Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS ONE, 2015, 10, e0141911.  | 2.5  | 80        |
| 166 | Acute hemodynamic effects of adaptive servoventilation in patients with pre-capillary and post-capillary pulmonary hypertension. Respiratory Research, 2015, 16, 137.  | 3.6  | 9         |
| 167 | Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.   | 27.0 | 790       |
| 168 | Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 348-355.  | 0.6  | 13        |
| 169 | Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 405-413.  | 6.7  | 184       |
| 170 | Veno-veno-arterial extracorporeal membrane oxygenation for respiratory failure with severe haemodynamic impairment: technique and early outcomes. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 761-767.  | 1.1  | 66        |
| 171 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.  | 6.7  | 2,415     |
| 172 | Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844.   | 27.0 | 906       |
| 173 | Performance of perfusion-weighted Fourier decomposition MRI for detection of chronic pulmonary emboli. Journal of Magnetic Resonance Imaging, 2015, 42, 72-79.   | 3.4  | 38        |
| 174 | Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal, 2015, 45, 1293-1302.  | 6.7  | 247       |
| 175 | Response to Letters Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPETE)" Circulation, 2014, 130, e110-2. | 1.6  | 5         |
| 176 | The changing landscape of pulmonary arterial hypertension and implications for patient care. European Respiratory Review, 2014, 23, 450-457.   | 7.1  | 122       |
| 177 | Chronic thromboembolic pulmonary hypertension at the crossroad. European Respiratory Journal, 2014, 43, 1230-1232.   | 6.7  | 9         |
| 178 | Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry: Table A1. BMJ Open Respiratory Research, 2014, 1, e000010.   | 3.0  | 22        |
| 179 | Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Annals of Thoracic Medicine, 2014, 9, 1.  | 1.8  | 11        |
| 180 | Extracorporeal Membrane Oxygenation Watershed. Circulation, 2014, 130, 864-865.  | 1.6  | 83        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 181 | Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. <i>International Journal of Cardiology</i> , 2014, 172, 332-339.         | 1.7  | 47        |
| 182 | Chronic thromboembolic pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2014, 2, 573-582.  | 10.7 | 146       |
| 183 | Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 319-329.   | 27.0 | 1,144     |
| 184 | Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.   | 2.8  | 1,467     |
| 185 | Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 1128-1138.  | 1.6  | 482       |
| 186 | Atrial flutter and fibrillation in patients with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 167, 2300-2305.  | 1.7  | 153       |
| 187 | Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.                  | 1.7  | 357       |
| 188 | Extracorporeal membrane oxygenation instead of invasive mechanical ventilation in patients with acute respiratory distress syndrome. <i>Intensive Care Medicine</i> , 2013, 39, 2056-2057.       | 8.2  | 85        |
| 189 | Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , 2013, 41, 1302-1307.                               | 6.7  | 131       |
| 190 | Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. <i>European Respiratory Journal</i> , 2013, 41, 853-860.  | 6.7  | 130       |
| 191 | Extracorporeal membrane oxygenation in a nonintubated patient with acute respiratory distress syndrome. <i>European Respiratory Journal</i> , 2012, 40, 1296-1298.                               | 6.7  | 32        |
| 192 | Extracorporeal Membrane Oxygenation in Awake Patients as Bridge to Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 763-768.                 | 5.6  | 539       |
| 193 | Plexiform Lesions in Pulmonary Arterial Hypertension. <i>American Journal of Pathology</i> , 2011, 179, 167-179.   | 3.8  | 144       |
| 194 | Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S45-S53.           | 1.7  | 61        |
| 195 | Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S54-S60.        | 1.7  | 93        |
| 196 | Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Circulation</i> , 2011, 124, 1973-1981.  | 1.6  | 860       |
| 197 | Osteopontin in Patients With Idiopathic Pulmonary Hypertension. <i>Chest</i> , 2011, 139, 1010-1017.   | 0.8  | 75        |
| 198 | Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1114-1124. | 5.6  | 259       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Virus-Associated Hemophagocytic Syndrome Contributes to Fatal Outcome In Critical Ill Patients with 2009 Influenza A (H1N1) Infection.. Blood, 2010, 116, 3795-3795.   | 1.4  | 0         |
| 200 | Definition, Classification, and Epidemiology of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 369-375.  | 2.1  | 72        |
| 201 | Chronic thromboembolic pulmonary hypertension: Evaluation with 64-detector row CT versus digital subtraction angiography. European Journal of Radiology, 2009, 71, 49-54.  | 2.6  | 130       |
| 202 | Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537. | 2.2  | 3,108     |
| 203 | Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S55-S66.   | 2.8  | 984       |
| 204 | Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S78-S84.   | 2.8  | 463       |
| 205 | Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.  | 2.8  | 506       |
| 206 | Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. Transplantation, 2008, 85, 524-531.  | 1.0  | 96        |
| 207 | Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. American Heart Journal, 2007, 153, 127-132.   | 2.7  | 243       |
| 208 | Sitaxentan in Pulmonary Arterial Hypertension. Drugs, 2007, 67, 771-772.   | 10.9 | 1         |
| 209 | Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology, 2006, 48, 2546-2552.  | 2.8  | 498       |
| 210 | Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. Circulation, 2006, 114, 1482-1489.   | 1.6  | 606       |
| 211 | Update in Pulmonary Hypertension 2005. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 499-505.   | 5.6  | 40        |
| 212 | Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2006, 113, 2011-2020.  | 1.6  | 791       |
| 213 | Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 536-537.  | 3.3  | 3         |
| 214 | Advances in Prostanoid Therapy: New Studies, New Methods of Delivery. Advances in Pulmonary Hypertension, 2006, 5, 23-30.  | 0.1  | 1         |
| 215 | Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2005, 128, 2363-2367.  | 0.8  | 166       |
| 216 | Drug Treatment of Pulmonary Arterial Hypertension. Drugs, 2005, 65, 1337-1354.   | 10.9 | 46        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 217 | Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278. | 2.2  | 903       |
| 218 | End points and clinical trial designs in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S48-S55.  | 2.8  | 147       |
| 219 | Portopulmonary hypertension and hepatopulmonary syndrome. Lancet, The, 2004, 363, 1461-1468.   | 13.7 | 440       |
| 220 | New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216.  | 5.6  | 129       |
| 221 | Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 341-344.  | 5.6  | 152       |
| 222 | A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. Journal of the American College of Cardiology, 2000, 35, 176-182.  | 2.8  | 296       |
| 223 | Splenectomy-Induced Portal Hypertension and Pulmonary Hypertension. Annals of Internal Medicine, 1999, 131, 793.   | 3.9  | 2         |
| 224 | Combination Therapy for Pulmonary Arterial Hypertension. , 0, , 127-145.   |      | 0         |
| 225 | Lung transplantation and severe coronary artery disease: results from a single-centre experience. European Journal of Cardio-thoracic Surgery, 0, , .  | 1.4  | 0         |